LEI 529900WGDQUZBNJOLD52
Boehringer Ingelheim RCV GmbH & Co KG
Group parent: C.H. Boehringer Sohn AG & Co. KG
Contract awards & public grants
Decoding the dark proteome through interdisciplinary training and research → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2026-06-11
—
Training program to engage flexible and disordered protein targets for therapeutic development: The oncogene β-catenin as showcase. → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2026-06-11
—
Deconstructing adaptive evolution of metastasis → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2024-07-05
€270,331
Greener, more sustainable platforms for high-value recombinant protein production → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2022-06-22
€270,331
Deconstructing the evolution of metastasis → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2020-09-03
€264,207
A new generation of microbial expression hosts and tools for the production of biotherapeutics and high-value enzymes → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2018-08-30
€264,207
Targeting the metabolism-immune system connections in Cancer → BOEHRINGER INGELHEIM RCV GMBH & CO KG
European Commission · AT · Grant · 2017-08-10
—
Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.